Articles tagged with Lung Cancer
Between 1975-2000, US lung cancer mortality declined significantly due to reduced smoking rates. Tobacco control measures such as increased taxes and smoke-free laws contributed to this decrease.
An NIH study found that tobacco control programs and policies have prevented over 795,000 lung cancer deaths in the US from 1975 through 2000. Further reductions are possible with continued and enhanced efforts.
Researchers identified ways to reduce costs of molecular profiling and targeted therapies, enabling more patients to benefit from personalized treatments. The methods include recommending testing only for high-risk patients and merging tests to lower combined prices.
A cohort study and nested case-control study found a statistically significantly increased risk of lung cancer with increasing diesel exhaust exposure among workers and urban populations. Studies suggest stringent occupational and environmental standards are necessary to reduce the health burden of carcinogenic diesel exhaust.
Breast cancer death rates are declining across the EU, with a predicted drop of 9% for women and 13% among young women. Pancreatic cancer deaths are rising, but overall cancer mortality rates are falling due to advancements in treatment and prevention.
New research highlights the importance of nurses in alleviating concerns and existential issues in newly diagnosed lung cancer patients. Nurses can provide supportive care, address death-related concerns, and help patients locate resources to manage end-of-life affairs.
Researchers discovered that manipulating two biochemical signals regulating mitochondria in cells can shrink human lung cancers in mice. By boosting fusion signal or blocking fission, they reduced cell division and increased cell death.
Lung cancer patients face geographic challenges to access clinical trials due to molecular preselection. Researchers propose using online patient communities and innovative trial approaches to inform patients about trials, accelerate research, and address practical challenges in conducting personalized medicine trials.
A new study published in CANCER found that many older lung cancer patients receive radiation therapy without extending their lifespan. Researchers analyzed data from the Surveillance, Epidemiology and End Results (SEER)-Medicare registry to determine if additional radiation therapy after surgery improves survival rates.
Researchers from Mount Sinai School of Medicine found that post-operative radiation therapy does not prolong life in older adults with locally advanced non-small cell lung cancer. The study analyzed data from over 1,300 patients and found no significant improvement in one-year or three-year survival rates.
IKBKE is induced by tobacco carcinogens and mediates tobacco action in promoting lung cancer cell survival. Knocking down IKBKE sensitizes cells to chemotherapy, suggesting a therapeutic role for targeting this pathway.
A recent study found that the STAT3 gene is activated in some non-small cell lung cancer cell lines by the JAK2 protein, which may not be effectively inhibited by drugs targeting specific mutations. This suggests a potential role for combination therapy to combat NSCLC driven by STAT3-JAK2 signaling.
Researchers developed a highly sensitive blood test for detecting and analyzing circulating tumor cells (CTCs) in cancer patients. The 'biopsy in a blood test' provides information comparable to surgical biopsies, enabling better monitoring, prediction, and understanding of cancer progression.
Different subgroups of non-small cell lung cancer exhibit distinct patterns of spread in the body, suggesting fundamentally different diseases. Targeted therapies have shown dramatic clinical responses in patients with ALK positive NSCLC, offering new hope for treatment.
Researchers at Massachusetts General Hospital have defined a new genetic subtype of lung cancer driven by ROS1 gene rearrangements. Crizotinib treatment has shown promising results in controlling tumors in patients with this subtype, offering a new therapeutic option.
A new lung cancer assay measures gene activity in tumor tissue and provides a risk score to predict patient survival after surgery. The assay has been validated in two independent trials and shows promise in identifying patients at highest risk of mortality.
A new molecular test can predict the likelihood of death from early-stage lung cancer with greater accuracy than traditional methods. The test, which measures gene activity in cancerous tissue, has been shown to improve prognosis and guide treatment decisions for patients with non-squamous non-small cell lung cancer.
A new study found that many cancer patients continue to smoke after diagnosis, with 39% of lung cancer and 14% of colorectal cancer patients smoking at diagnosis. Factors such as insurance, emotional support, and education level can predict continued smoking in these patients.
Researchers found that MET gene overexpression leads to deregulation of microRNAs, causing gefitinib resistance in lung cancer. Combining targeted drugs with microRNA blockers may improve treatment efficacy.
Researchers decoded the behavior of lysozymes, a protein in teardrops that chomps through bacterial cell walls. The discovery could lead to early detection and treatment of cancers.
Scientists have documented how ALK positive advanced non-small cell lung cancer becomes resistant to crizotinib, a previously effective treatment. Researchers now aim to develop combination therapies to tackle this resistance and improve patient outcomes.
Research finds a significant association between pulmonary TB and EGFR mutations in lung cancer patients. The study reveals that tumors with these mutations respond well to targeted therapies, offering new hope for treatment.
In a preclinical study, ganetespib slowed the growth of cancer cells from non-small cell lung tumors with a KRAS gene mutation. The drug was more active when combined with traditional lung cancer treatments and other targeted therapies, indicating its potential effectiveness in treating patients with KRAS-mutant NSCLC.
Researchers found significant cancer-like gene expression changes in healthy smokers' large airway epithelia compared to nonsmokers. The study suggests smoking induces molecular alterations in the large airway epithelium prior to disease development, making it a primary site for lung cancer risk.
Researchers found sorafenib to be effective in patients with non-small cell lung cancer and a KRAS mutation, achieving a 52.6% rate of no progression at six weeks. However, median overall survival was only 5.3 months, indicating unsatisfactory outcomes.
A preclinical study found that a combination of estrogen-targeting drugs significantly reduced tobacco carcinogen-induced lung tumors in mice. The treatment, which blocks estrogen production and its effects on the body, showed maximum antitumor effects in both healthy and precancerous cells.
Research finds that multicentric lung adenocarcinoma often shares the same genetic mutation, indicating a possible common origin for these tumors. The study identified genetically distinct molecular subsets using EGFR and KRAS genes.
Researchers developed a sensitive test to analyze circulating tumor cells in blood, enabling clinicians to track cancer progress and treatments. The method uses high-throughput mass spectrometry analysis, allowing for the detection of genetic mutations present in small numbers of malignant cells.
TGen researchers identify multiple novel mutations and pathway changes in never-smoker lung cancer patients, diverging from those found in smokers. These findings hold promise for developing therapeutic targets in this patient population.
Researchers identified potential gene mutations and pathway alterations that could lead to lung cancer in never-smokers. They found that these patients' tumors lacked common genes associated with lung cancer, making them ideal cases for discovering new mutations that may drive the disease.
A malignancy-risk gene signature developed for breast cancer has been found to have predictive and prognostic value for patients with early stage non-small cell lung cancer. The signature was able to distinguish between low and high malignancy risk groups, correlating with good or poor overall survival rates.
Researchers have identified a previously unknown gene fusion event in lung adenocarcinoma cases in never-smokers, suggesting that this fusion could serve as a therapeutic target. The study found the KIF5B-RET fusion to occur in about 6% of all lung adenocarcinoma cases.
A Wayne State University study shows that soybean compounds can make radiation treatment of lung cancer more effective while helping to preserve normal tissue. The compounds, known as isoflavones, block DNA repair mechanisms and molecular survival pathways in cancer cells, making them more vulnerable to ionizing radiation.
The IASLC has set up a Strategic CT Screening Advisory Committee to define optimal approaches to lung cancer screening. The committee will focus on six key components, including identifying high-risk individuals and developing radiological guidelines for national screening programs.
Researchers identified STARD9, a kinesin-like protein involved in cell division, as a potential target for cancer therapy. Depleting STARD9 stops cancer cells from dividing and causes them to die quickly, showing promise in treating certain types of melanoma and non-small cell lung cancers.
Researchers found a strong association between smoking and squamous cell carcinoma in women, with increased risk seen with higher cigarette consumption. Smoking history was more strongly linked to SCC in women than men, with a four-fold increase in those who had smoked for 20 years or more.
Researchers found that COPD patients are 5 times more likely to develop lung cancer than normal smokers. Early detection of COPD through lung function testing can help identify high-risk patients for lung cancer screening.
Researchers found that silibinin from milk thistle prevents lung cancer growth by inhibiting COX2 and iNOS production. This natural compound may be as effective as current treatments for lung cancer, targeting promising therapeutic targets STAT1 and STAT3.
A combination epigenetic therapy has shown positive effects in a small clinical trial of late-stage lung cancer patients. The treatment increased median survival by two months and showed complete or near-complete responses in some patients. Researchers believe the therapy may reprogram gene expression to prevent cancer growth.
Patients with high EGFR expression have a survival advantage when treated with cetuximab plus chemotherapy, living up to 12 months on average. In contrast, those with low EGFR expression show no difference in overall survival.
A study found that organ transplant recipients have a doubled cancer risk compared to the general population, with increased risks for various types of malignancies, including non-Hodgkin lymphoma and lung cancer. The increased risk is attributed to immunosuppression and oncogenic viral infections.
The algorithm identifies high-risk patients for gastro-oesophageal and lung cancers at an earlier stage by analyzing symptoms and risk factors. It shows that the top 10% of predicted patients accounted for 77% of all diagnosed cases over two years.
A study published in JAMA suggests that CT scans used for lung cancer screening can help identify chronic obstructive pulmonary disease (COPD) in heavy smokers. The research found that adding an expiratory CT scan to the baseline inspiratory scan improved diagnostic accuracy, particularly for individuals with severe obstruction.
Researchers found that UK doctors are reluctant to cite smoking as a cause of death on death certificates due to concerns about stigmatizing the deceased. In contrast, alcohol was cited as a cause in over half of cases linked to excessive drinking.
A phase 2 trial shows that combining standard chemotherapy with a new cancer vaccine enhances treatment effect and slows disease progression in NSCLC patients. The vaccine stimulates an immune response against the MUC1 protein, which is overexpressed in 60% of NSCLCs.
The Boston University School of Medicine is developing novel technologies to detect lung cancer early, using advanced imaging techniques and molecular biomarkers. The goal is to reduce mortality among high-risk individuals by identifying those at risk for future development of the disease.
Researchers found that lung cancer patients with diabetes had higher survival rates, including 43% at 1-year and 28% without diabetes. The benefits were seen across different stages of disease, suggesting that diabetes may not be a reason to withhold standard treatment.
A new system being developed by researchers at the University of Strathclyde could administer drugs to lung cancer patients more efficiently without harmful side effects. The approach involves delivering treatment via nebulisation, potentially leading to improved patient outcomes and reduced mortality rates.
Advanced PET scans can identify aggressive tumors and predict patient prognosis, potentially intensifying treatment for patients with locally advanced lung cancer. The study found a strong correlation between radiation dose intensity and local control of the cancer.
Researchers have developed a virtual fly-through 3D imaging technique that accurately detects regional lymph node metastases in non-small cell lung cancer patients. The method achieved an 81% diagnostic accuracy rate, making it a promising tool for non-invasive diagnosis.
A randomized phase III trial found that higher doses of radiation therapy do not improve overall survival for stage III non-small cell lung cancer patients. The standard dose of radiation therapy (60 Gy) was shown to be sufficient and effective in treating the disease.
A new type of MRI scan, diffusion-weighted MRI, has been shown to be more accurate in detecting lung cancer than current PET-CT scans. This non-invasive technique measures water movement in lung tissue and can detect structural changes caused by cancer even in early stages.
A French study found professional goat exposure increases risk of pneumonic-type lung adenocarcinoma (P-ADC) fivefold compared to other lung cancers. P-ADC is more common in females and those with no smoking history.
A University of Kentucky research team, led by Dr. Susanne Arnold, has been awarded a $1.43 million grant to investigate potential environmental factors contributing to the high lung cancer rates in Eastern Kentucky. The study will examine exposure to trace elements and their role in promoting carcinogenesis.
Researchers at the University of Missouri have developed a nanotechnology sensor that can detect lung cancer in blood plasma with high sensitivity and selectivity. This technology could provide an earlier warning signal, potentially saving lives. The sensor detects changes in a specific microRNA molecule associated with lung cancer.
Researchers have identified protein signatures in mouse blood samples that reflect lung cancer biology in humans, paving the way for better monitoring of tumor progression and potential early detection strategies. The study's findings also suggest that these signatures may be useful in detecting lung cancer at an earlier stage.
Researchers at Brigham and Women's Hospital have identified a new combination of targeted therapies that successfully treat two aggressive tumor types: neurofibromatosis type 1 and KRAS-mutant lung cancer. The treatment promotes dramatic tumor regression by targeting cancer cells from two different angles.
A new study found that lung cancer patients treated in hospitals with high safety-net burden faced significantly lower rates of curative-intent surgery compared to those at low-safety-net burden facilities. The disparity persisted even after controlling for other factors.
A study published in The Lancet found that World Trade Center-exposed New York City male firefighters are 19% more likely to have cancer compared to their non-exposed colleagues, as well as a comparable sample of the general population. The study analyzed data from 9853 male firefighters and found increased cancer incidence rates in WT...
A study found that ALK-rearranged non-small cell lung cancer patients responded significantly better to pemetrexed than those without the genetic mutation. Researchers discovered that ALK positivity was an independent predictor for pemetrexed efficacy, with improved tumor response rates and longer time to progression.